Analysts think ARTV stock price could increase by 936%
Apr 14, 2025, 11:25 AM
3.81%
What does ARTV do
Artiva Biotherapeutics, based in San Diego, focuses on NK cell-based therapies for autoimmune diseases and cancers, with its lead candidate AlloNK in Phase I/Ib trials. The company went public on July 19, 2024.
7 analysts think ARTV stock price will increase by 935.53%. The current median analyst target is $20.40 compared to a current stock price of $1.97. The lowest analysts target is $18.18 and the highest analyst target is $24.15.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
